Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) is a clinical-stage biopharmaceutical company that reports frequent updates related to its work in genetically defined rare diseases. Company news regularly highlights progress for its lead program, pociredir, an investigational oral small molecule designed to increase fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD).
Investors and followers of FULC can expect news items covering clinical trial milestones, such as initial and updated data from the Phase 1b PIONEER trial of pociredir in adults with severe SCD. Fulcrum’s releases describe dose-escalation cohorts, changes in HbF levels, markers of hemolysis and anemia, and observations related to vaso-occlusive crises, along with safety and tolerability findings.
Fulcrum also issues corporate and financial announcements, including quarterly financial results, cash runway commentary, and details of public offerings of common stock and pre-funded warrants. Additional news may feature participation in major medical and investor conferences, such as the American Society of Hematology Annual Meeting and the J.P. Morgan Healthcare Conference, where the company presents clinical and preclinical data.
Other updates include disclosures on early-stage programs, such as calmodulin pathway modulators for bone marrow failure syndromes and preclinical data for EED inhibitor candidates in oncology models, as well as routine items like inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). For readers tracking FULC, this news stream provides insight into the evolution of Fulcrum’s pipeline, its clinical development strategy in sickle cell disease, and its broader efforts in gene-expression modulation for rare diseases.
Fulcrum Therapeutics (Nasdaq: FULC) recently presented promising data on losmapimod, a treatment for facioscapulohumeral muscular dystrophy (FSHD), at the American Academy of Neurology Annual Meeting. The presentations outlined clinical data supporting losmapimod's potential to slow disease progression. The company plans to initiate the Phase 3 REACH trial in Q2 2022, aiming to enroll approximately 230 adults. Losmapimod has received FDA Fast Track and Orphan Drug Designation, highlighting its significance as a potential therapeutic option for FSHD.
Fulcrum Therapeutics (Nasdaq: FULC) will host a Key Opinion Leader meeting on March 24, 2022, to discuss the unmet need in facioscapulohumeral muscular dystrophy (FSHD) and their Phase 3 REACH trial for losmapimod, an investigational treatment. Esteemed experts Dr. Nicholas Johnson and Dr. Jay Han will join company executives for insights on disease progression and treatment landscape. FSHD affects 16,000 to 38,000 in the U.S., causing debilitating symptoms with no approved treatments available. Registration for the webcast is available on their website.
Fulcrum Therapeutics (NASDAQ: FULC) announced significant findings demonstrating that Reachable Workspace (RWS) effectively measures functionality in patients with facioscapulohumeral muscular dystrophy (FSHD). Data from two Phase 2 studies indicated that losmapimod, an investigational treatment, preserved or improved function as measured by RWS. The company is set to begin the Phase 3 REACH trial in Q2 2022, enrolling approximately 230 adults. RWS will serve as the primary endpoint, emphasizing the need for objective measures of disease progression.
Fulcrum Therapeutics (Nasdaq: FULC) announced the granting of nonstatutory stock options to four new employees as part of its 2022 Inducement Stock Incentive Plan. A total of 31,520 stock options were awarded on March 7, 2022, each with an exercise price of $14.90, equal to the closing price of FULC's common stock on that date. The options will vest over a four-year period, starting with 25% vesting on the first anniversary of the employees’ start dates. The company focuses on treating genetically defined rare diseases.
Fulcrum Therapeutics (FULC) announced significant progress in its clinical trials during a business update on March 3, 2022. The company is set to initiate the Phase 3 REACH trial for losmapimod in the treatment of facioscapulohumeral muscular dystrophy (FSHD) by 2Q 2022, aiming to demonstrate efficacy and safety. Additionally, initial data from a Phase 1b trial for FTX-6058 in sickle cell disease is expected in 2Q 2022. Fulcrum reported a loss of $80.8 million for 2021 but ended the year with $218.2 million in cash, expected to sustain operations through 2024.
Fulcrum Therapeutics (NASDAQ: FULC) announced plans to initiate the REACH Phase 3 clinical trial of losmapimod for facioscapulohumeral muscular dystrophy (FSHD) in Q2 2022. FSHD is a debilitating disease with no approved treatments. The trial, which received alignment from the FDA and EU agencies, aims to enroll around 230 adults and assess losmapimod's efficacy in improving daily function. Previous Phase 2b results indicated promising outcomes in slowing disease progression. A key opinion leader webcast on FSHD is scheduled for March 24, 2022.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced it will release its fourth quarter and full year 2021 financial results on March 3, 2022, prior to U.S. market opening. A conference call will occur at 8:00 a.m. ET to discuss the results and corporate developments. Fulcrum focuses on addressing rare diseases through its leading programs: losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058 for sickle cell disease. The company utilizes its proprietary FulcrumSeek™ engine to identify drug targets.
Fulcrum Therapeutics (NASDAQ: FULC) announced on February 11, 2022, the grant of inducement awards to Amy Winnen, the new Vice President, Head of Market Value, Access and Policy. The award includes a nonstatutory option to purchase 43,260 shares at an exercise price of $10.93, the closing price on February 7, 2022. Approved by independent directors, the option vests over four years and is part of Nasdaq Listing Rule compliance. Fulcrum focuses on developing treatments for genetically defined rare diseases, with lead programs targeting facioscapulohumeral muscular dystrophy and sickle cell disease.
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company focusing on genetically defined rare diseases, announced participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 9:20 a.m. ET. A live audio webcast will be available on their investor relations website, with an archived replay accessible for 30 days. Fulcrum's lead programs include losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 targeting sickle cell disease.
Fulcrum Therapeutics announced the first patient has been dosed in the Phase 1b trial of FTX-6058 for sickle cell disease, with initial data expected in 2Q 2022. An IND submission for FTX-6058 to support trials in select hemoglobinopathies is also planned for 2Q 2022. The company aims to provide updates on losmapimod in 1Q 2022. Kate Haviland has been appointed chair of the board of directors. Fulcrum reported a cash position of $218.2 million as of December 31, 2021, sufficient to fund operations into 2024.